Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-08
2008-01-08
Anderson, Rebecca (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S159000, C548S217000, C548S148000, C514S367000, C514S375000
Reexamination Certificate
active
10503585
ABSTRACT:
Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I): wherein R1is optionally substituted aryl or optionally substituted heteroaryl, R2is lower alkyl; R3is hydroxy or protected hydroxy; X is O or S; and -A- is lower alkylene, its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective
REFERENCES:
patent: 6359145 (2002-03-01), Terasaka et al.
patent: 6596738 (2003-07-01), Terasaka et al.
patent: 6908940 (2005-06-01), Tsuji et al.
patent: 2004/0097571 (2004-05-01), Tsuji et al.
patent: 2004/0236114 (2004-11-01), Terasaka et al.
patent: 92 18483 (1992-10-01), None
patent: 95 24395 (1995-09-01), None
patent: 00 55155 (2000-09-01), None
patent: WO 01/26605 (2001-04-01), None
patent: 01 53271 (2001-07-01), None
Patani et al., “Bioisosterism: A Rational Approach in Drug Design”; Chem. Rev. 1996, vol. 96, p. 3147-3176.
www.acdlabs.com/iupac
omenclature/79/r79—983.htm; “Heterocyclic Systems, Rule B-5. Radicals”, 3 pages.
http://cancer.about.com/od/leukemia/a/leukemiaprevent.htm, p. 1 of 1.
http://en.wikipedia.org/wiki/Prodrug, 2 pages.
Han et al., “Targeted Prodrug Design to Optimize Drug Delivery”, AAPS PharmSci. 200, 2(1), article 6, DOI:10.1208/ps020106.
http://en.wikipedia.org/wiki/Levodopa, 4 pages.
http://en.wikipedia.org/wiki/Autoimmune—disease, 6 pages.
http://bccc.pair.com/autoimmu.htm, 3 pages.
http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm.
Kuno et al., “Anti-inflammatory activity of non-nucleosie adenosine deaminase inhibitor FR234938”, European Journal of Pharmacology, 534 (2006), 241-249.
Barnes, P.J. “Mediators of Chronic Obstructive Pulmonary Disease”, Pharmacol. Rev. 56 (2004), 515-548.
Kay, A.B. “Allergy and Allergic Diseases, First of Two Parts”, N. Engl J Med, vol. 344, p. 30-37.
McCulloch et al. “Signalling Platforms that modulate the inflammatory response: new targets for drug development”, Nature Reviews/Drug Discovery, vol. 5 (2006), 864-876.
http//www.mayoclinic.com/health/periodontitis/DS00369/DSECTION=7, 2 pages.
Singh et al. “Differential Expression of Inflammatory Cytokines and Chemokines Genes by Homocystein in the Human Retinal Pigmented Epithelial Cells”, FASEB, 2006, 20, A719 (abstract).
http://www.emedicinehealth.com/leukemia/page12—em.htm, 2 pages.
Terasaka et al. “Structure-Based Design and Synthesis of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors”, J. Med. Chem. 2004, 47, 2728-2731.
Grever et al. “Pentostatin in the treatment of hairy cell leukemia”, Best Practice & Research Clinical Haematology, vol. 16, p.l 91-99.
Cristalli, Gloria et al. “Adenosine Deaminase Inhibitors: Synthesis and Structure- Activity Relationships of Imidazole Analogues of erythro-9-(2-Hydroxy-3-nonyl)adenine”. Journal of Medicinal Chemistry, vol. 34, No. 3, pp. 1187-1192, XP002119563, ISSN: 0022-2623 1991.
Kato Takeshi
Konishi Nobukiyo
Nakamura Katsuya
Terasaka Tadashi
Tsuji Kiyoshi
Anderson Rebecca
Astellas Pharma Inc.
Loewe Sun Jae Y
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
LandOfFree
Imidazole 4-carboxamide compounds with adenosine deaminase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazole 4-carboxamide compounds with adenosine deaminase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazole 4-carboxamide compounds with adenosine deaminase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3907845